Discovery of CC-90003: A covalent ERK1/2 inhibitor

被引：0
|
作者：
Qiao, Li-Xin [1 ]
机构：
[1] Celgene Corp, Cambridge, MA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2017年 / 254卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
26
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ERK1/2 EXPRESSION IN GLIOBLASTOMA MULTIFORME
    Sica, G.
    Lama, G.
    Mangiola, A.
    De Silvestri, S.
    Sabatino, G.
    Anile, C.
    Giannitelli, C.
    Maira, G.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3631 - 3632
  • [42] Reishi hydrolysate as Erk1/2 phosphorylation inhibitor: Explore the inhibitory mechanism by proteomics approach
    Krobthong, Sucheewin
    Choowongkomon, Kiattawee
    Yingchutrakul, Yodying
    CANCER SCIENCE, 2021, 112 : 884 - 884
  • [43] Inhibition of the ERK1/2 pathway by RanBPM
    Atabakhsh, Elnaz
    Schild-Poulter, Caroline
    CANCER RESEARCH, 2012, 72
  • [44] Cheminformatics-based differential modeling of dynamic ERK1/2-inhibitor interactions
    Ash, Jeremy
    Hughes-Oliver, Jacqueline
    Fourches, Denis
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [45] A novel mechanism of ERK1/2 regulation in smooth muscle involving acetylation of the ERK1/2 scaffold IQGAP1
    Vetterkind, Susanne
    Lin, Qian Qian
    Morgan, Kathleen
    FASEB JOURNAL, 2015, 29
  • [46] The dimer interface of ERK1/2 provides an alternative targeting strategy to interfere with ERK1/2 mediated cardiac hypertrophy
    Tomasovic, A.
    Huemmert, M.
    Kramer, S.
    Gruse, T.
    Katus, H. A.
    Lohse, M. J.
    Mueller, O.
    Lorenz, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S4 - S5
  • [47] ERK1 and ERK2 are essential for osteoblast differentiation.
    Matsushita, T.
    Landreth, G.
    Murakami, S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S41 - S41
  • [48] The role of ERK1 and ERK2 in T cell development
    Fischer, AM
    Hedrick, SM
    FASEB JOURNAL, 2005, 19 (04): : A922 - A922
  • [49] MAPK signalling: ERK5 versus ERK1/2
    Nishimoto, Satoko
    Nishida, Eisuke
    EMBO REPORTS, 2006, 7 (08) : 782 - 786
  • [50] ASTX029 is a dual mechanism ERK1/2 inhibitor with activity in models of MAPK-inhibitor resistance
    Zhang, Zhiqiang
    Hindley, Christopher
    Biondo, Andrea
    Wallis, Nicola
    Lyons, John
    Munck, Joanne
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345